News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,727 Results
Type
Article (8022)
Company Profile (140)
Press Release (476564)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166750)
Career Advice (304)
Deals (25740)
Drug Delivery (7)
Drug Development (52876)
Employer Resources (14)
FDA (9760)
Job Trends (8573)
News (238205)
Policy (17899)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33156)
ALS (105)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (264)
Approvals (10378)
Artificial intelligence (321)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6959)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (510)
Cancer (3653)
Cardiovascular disease (218)
Career advice (245)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (47877)
Collaboration (1245)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (754)
CRISPR (63)
C-suite (752)
Cystic fibrosis (85)
Data (5662)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (344)
Diagnostics (4186)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (155)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73723)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87625)
Executive appointments (701)
FDA (12398)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (919)
Gene editing (125)
Generative AI (9)
Gene therapy (318)
GLP-1 (290)
Government (943)
Grass and pollen (2)
Guidances (281)
Healthcare (9318)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (157)
Infectious disease (942)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (255)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (534)
Marketing (8)
MASH (118)
Medical device (8658)
Medtech (8803)
Mergers & acquisitions (14386)
Metabolic disorders (709)
mRNA (56)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (39)
Neuroscience (1826)
NextGen: Class of 2026 (3150)
Non-profit (841)
Obesity (225)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (508)
Peanut (31)
People (41243)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15470)
Phase 2 (21383)
Phase 3 (14402)
Pipeline (7344)
Policy (18)
Postmarket research (1570)
Preclinical (6539)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (575)
Real estate (3019)
Recruiting (6)
Regulatory (14831)
Reports (21)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (156)
Series B (121)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (324)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (45)
Last 7 days (211)
Last 30 days (1589)
Last 365 days (19038)
2026 (12348)
2025 (19251)
2024 (22986)
2023 (26538)
2022 (34594)
2021 (37179)
2020 (33471)
2019 (23259)
2018 (17495)
2017 (18766)
2016 (17917)
2015 (24264)
2014 (21684)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17894)
Australia (2098)
California (11991)
Canada (3149)
China (524)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24630)
Florida (1790)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (700)
India (51)
Indiana (314)
Iowa (15)
Japan (403)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1202)
Massachusetts (7862)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2621)
New Mexico (12)
New York (2823)
North Carolina (1280)
North Dakota (4)
Northern California (6006)
Ohio (278)
Oklahoma (14)
Oregon (16)
Pennsylvania (2253)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4983)
Tennessee (120)
Texas (1942)
United States (38908)
Utah (361)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
484,727 Results for "pfenex inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ligand to Acquire Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Pfenex Inc. (NYSE American: PFNX) today announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis
August 10, 2020
·
15 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Deals
Ligand Completes Acquisition of Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved
October 1, 2020
·
15 min read
Deals
Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform
Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.
August 11, 2020
·
3 min read
·
Mark Terry
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
Press Releases
Biogen Completes Acquisition of RayThera Inc.
August 7, 2026
·
7 min read
Deals
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a cont
August 31, 2020
·
8 min read
Deals
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain specified milesto
September 30, 2020
·
5 min read
Press Releases
Therma Bright Inc. Completes Debt Settlements
July 30, 2026
·
3 min read
Press Releases
Utah Medical Products, Inc. Announces Quarterly Dividend
August 4, 2026
·
1 min read
1 of 48,473
Next
